Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SAB Biotherapeutics, Inc.BCYP · Entity 5816 | Director · 10% owner | October 13, 2021 | October 15, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SAB Biotherapeutics, Inc.
Report date October 13, 2021 · Filed October 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,500 |
Reported balance
After 2021-10-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-10-13 · Purchase · Acquired 500 · Balance 1,500 F1: Represents 500 shares of the issuer's common stock acquired by the reporting person in open market transactions. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,047,825 |
Reported balance
Holding disclosure · report date 2021-10-13 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,047,825 F2: Includes 3,047,825 shares of the issuer's common stock held directly by Big Cypress Holdings LLC (the "Sponsor") and indirectly by Samuel J. Reich and Ilan Katz as managers of the Sponsor, which includes 417,200 private placement units of the issuer. The private placement units were purchased in a private placement that closed simultaneously with the closing of the issuer's initial public offering, and each such unit consists of one share of common stock of the issuer and one-half of one warrant of the issuer. The warrants included in the units will become exercisable, if at all, on the later of 30 days after the completion of the issuer's initial business combination and 12 months from the closing of the issuer' initial public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 500 shares of the issuer's common stock acquired by the reporting person in open market transactions.
F2: Includes 3,047,825 shares of the issuer's common stock held directly by Big Cypress Holdings LLC (the "Sponsor") and indirectly by Samuel J. Reich and Ilan Katz as managers of the Sponsor, which includes 417,200 private placement units of the issuer. The private placement units were purchased in a private placement that closed simultaneously with the closing of the issuer's initial public offering, and each such unit consists of one share of common stock of the issuer and one-half of one warrant of the issuer. The warrants included in the units will become exercisable, if at all, on the later of 30 days after the completion of the issuer's initial business combination and 12 months from the closing of the issuer' initial public offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2021 Filed Oct 15, 2021 14:51 UTC | SAB Biotherapeutics, Inc. BCYP · Entity 5816 | PurchaseCommon Stock | 500 | $10.11 | $5,052.50 |
DisclosureSEC source: 0001493152-21-025510 · ownership.xml · nonDerivative · entry 1 Katz Ilan · CIK 0001838085 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 F1 · kind: Represents 500 shares of the issuer's common stock acquired by the reporting person in open market transactions. F1 · ownership.direct: Represents 500 shares of the issuer's common stock acquired by the reporting person in open market transactions. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:00 UTC | SAB Biotherapeutics, Inc. BCYP · Entity 5816 | PurchaseCommon Stock | 1,000 | $10.09 | $10,090.00 |
DisclosureSEC source: 0001493152-21-024640 · ownership.xml · nonDerivative · entry 1 Katz Ilan · CIK 0001838085 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: Represents 1,000 shares of the issuer's common stock acquired by the reporting person in open market transactions. F2 · ownership.direct: Includes 3,047,825 shares of the issuer's common stock held directly by Big Cypress Holdings LLC (the "Sponsor") and indirectly by Samuel J. Reich and Ilan Katz as managers of the Sponsor, which includes 417,200 private placement units of the issuer. The private placement units were purchased in a private placement that closed simultaneously with the closing of the issuer's initial public offering, and each such unit consists of one share of common stock of the issuer and one-half of one warrant of the issuer. The warrants included in the units will become exercisable, if at all, on the later of 30 days after the completion of the issuer's initial business combination and 12 months from the closing of the issuer' initial public offering. Read SEC document |
| January 14, 2021 Filed Jan 14, 2021 18:32 UTC | SAB Biotherapeutics, Inc. BCYP · Entity 5816 | PurchaseCommon Stock | 417,200 | $10.00 | $4,172,000.00 |
DisclosureSEC source: 0001493152-21-001029 · ownership.xml · nonDerivative · entry 1 Katz Ilan · CIK 0001838085 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Via Big Cypress Holdings LLC Disclosed balance after: 3,047,825 F1 · kind: The reported shares are included within the 417,200 private placement units of the issuer purchased by Big Cypress Holdings LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the issuer's initial public offering, and each such unit consists of one share of common stock of the issuer and one-half of one warrant of the issuer. The warrants included in the units will become exercisable, if at all, on the later of 30 days after the completion of the issuer's initial business combination and 12 months from the closing of the issuer' initial public offering. The securities are held directly by the Sponsor and indirectly by Samuel J. Reich and Ilan Katz as managers of the Sponsor. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.